NCT02753127 2023-11-15CanStem303CSumitomo Pharma America, Inc.Phase 3 Completed1,253 enrolled 18 charts
NCT04299880 2023-11-08Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsSumitomo Pharma America, Inc.Phase 1 Completed7 enrolled
NCT02759588 2023-01-05GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerGenelux CorporationPhase 1/2 Completed46 enrolled